Comparison of 0.5% Intrathecal Bupivacaine With 0.5% Intrathecal Ropivacaine in the Treatment of Refractory Cancer and Noncancer Pain Conditions: Results From a Prospective, Crossover, Double-Blind, Randomized Study
Comparison of 0.5% Intrathecal Bupivacaine With 0.5% Intrathecal Ropivacaine in the Treatment of Refractory Cancer and Noncancer Pain Conditions: Results From a Prospective, Crossover, Double-Blind, Randomized Study